

Nationwide Survey Says 10% of HIV Is Resistant

BY TIMOTHY F. KIRN
Sacramento Bureau

LOS ANGELES — Surveillance data indicate that 10% of people in the United States who become infected with HIV have acquired a virus with some resistance, Dr. Ulana Bodnar said at the 14th Conference on Retroviruses and Opportunistic Infections.

The 11-state survey represents the largest survey done to date regarding HIV

resistance. The survey, which looked at specimens from 3,130 newly diagnosed, drug-naive individuals, found that 4% of infections had mutations conferring resistance to nucleoside reverse transcriptase inhibitors, 7% to nonnucleoside reverse transcriptase inhibitors, and 2% to protease inhibitors.

The percentages add up to more than 10% because some viruses were resistant to more than one class of drug.

Multidrug resistance was found in 2% of

individuals, with 0.5% having resistance to drugs in all three classes, reported Dr. Bodnar, of the Centers for Disease Control and Prevention, Atlanta.

Overall, 94% were infected with subtype B virus. After subtype B, subtypes C and CRF02-AG were the most common, accounting for 2% and 1% of the infections, respectively, he said in a poster presentation.

The non-B variants were somewhat less likely to have resistance than were the B subtypes (8% vs. 11%); however, the

difference was not statistically significant.

The findings of the survey “are consistent with what other studies have shown over the past 5 years,” Dr. Bodnar said in an interview. “It is a good baseline with which to consider the data we get down the road.”

The 11 states included in the survey were Colorado, Illinois, Louisiana, Maryland, Massachusetts, Michigan, Mississippi, North Carolina, South Carolina, Virginia, and Washington. The specimens came from a total of 409 sites. ■

MANAGING *Migraines* MAY REQUIRE MORE THAN A QUICK FIX.

Ask how frequent, disruptive migraines may impact her both during and between attacks. Choose TOPAMAX to help reduce migraine frequency.^{1,2}

Life shouldn't always revolve around migraines.

TOPAMAX[®]
(topiramate) Tablets

www.topamax360.com

 ORTHO-McNEIL NEUROLOGICS, INC.

 Together Rx Access
is a trademark of
Together Rx Access, LLC.

© OMN, Inc. 2007

March 2007

02M931A

R_x

Important

Avoid confusion with Toprol-XL[®] (metoprolol succinate) by spelling out TOPAMAX[®] (topiramate) on your prescription. Toprol-XL is a registered trademark of the AstraZeneca group of companies.

Please see brief summary of full Prescribing Information on following pages.

References: 1. Silberstein SD, Neto W, Schmitt J, Jacobs D, for the MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. *Arch Neurol*. 2004;61:490-495. 2. Brandes JL, Saper JR, Diamond M, et al, for the MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. *JAMA*. 2004;291:965-973.